Let's go inside out on this name and weight loss drugs across the space. Joining us now is Tom Kulick, CEO, Strategy Asset Managers. Thank you so much for joining me. >> Thank you. Thank you.Happy holidays. >> Yeah, happy holidays to you as well. Thanks so much for being on the floor with us this morning.Look, um let's talk about Eli Lily. It's been doing some good things lately and it's been rewarded. >> Yes, they they have.So, last week they came out with the results from some of the trials that they have ...

Core Insights - The demand for GLP-1 obesity drugs is growing, with projections indicating a potential market exceeding $100 billion in the long term [2][3] - Eli Lilly and Novo Nordisk are currently the leading players in the GLP-1 market, with Lilly's Zepbound being highlighted as the most effective product [3][5] - The competitive landscape is evolving, with new entrants expected, but the market is still dominated by Lilly and Novo due to their established manufacturing capabilities [16][17] Demand and Market Growth - Demand for GLP-1 drugs continues to grow, with manufacturing now keeping pace with this demand [2] - The market for these drugs is anticipated to exceed $100 billion in the long term, indicating significant growth potential [2] Competitive Landscape - The market is viewed as a two-horse race between Eli Lilly and Novo Nordisk, with Lilly currently taking the lead due to its effective product [3][4] - Zepbound has shown superior weight loss results in head-to-head studies, making it difficult for competitors to match its effectiveness [5] Product Development and Innovation - Lilly's retatrutide is in stage three of development and is expected to potentially outperform Zepbound [6] - Pfizer's acquisition of Metera is seen as a necessary move after its own GLP-1 product failed to meet expectations [7] Pricing and Market Dynamics - The introduction of oral GLP-1 medications is anticipated, but injectables are expected to remain the primary sales driver due to their effectiveness [12][10] - As more products enter the market, there may be downward pressure on prices, although current prices remain high [14] Manufacturing and Capacity - Only Eli Lilly and Novo Nordisk have built the necessary manufacturing capacity for GLP-1 injectables at scale, providing them with a significant competitive advantage [16][17] - Eli Lilly has invested over $50 billion in U.S. manufacturing since 2020, indicating strong commitment to maintaining its market position [18] Macro Environment and Industry Outlook - The GLP-1 market dynamics are unique to Eli Lilly and Novo Nordisk, with these companies experiencing specific tailwinds despite broader industry headwinds [19]